Home|Journals|Articles by Year|Audio Abstracts

Original Research

Neutrophil Lymphocyte Ratio in Patients Receiving Isotretinoin for Acne Vulgaris

Arzu Ataseven, Gulcan Saylam Kurtipek, Perihan Ozturk.


The aim of this study is to assess the neutrophil, lymphocyte and neutrophil lymphocyte ratio in patients receiving isotretinoin for acne treatment. 110 (64 women, 46 men) patients with acnevulgaris were included in this study. Patients were treated with 0.5-1 mg/kg/day isotretinoin. The laboratory results were collected retrospectively from the patients’ records. Neutrophils, lymphocytes, and neutrophils lymphocytes ratio before treatment and at the third months after the treatment were collected retrospectively. Statistical analysis was performed using PASW Statistics 18. Paired sample T-test was used to compare pre-and post treatment parameters. The mean number of neutrophils in patients with pre-treatment and post-treatment were; 4354±1623 and 4147±1659, the mean lymphocyte counts were 2410±716 and 2384±681 and NLO values before and after treatment were 2.06 ±1.42 and 2.00 ±1.99, respectively. There is no statistically significant difference for the three values (p> 0.05). The effect of isotretinoin therapy in patients with acne vulgaris is not determined on neutrophil and lymphocyte counts and neutrophil lymphocyte ratio.

Key words: Acne, neutrophil, lymphocyte, neutrophil lymphocyte ratio

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.